KR19990056904A - Hangover treatment composition - Google Patents

Abstract

The present invention relates to a composition for treating a hangover resulting from alcohol overdose, at least 50% by weight of potassium salt, 20-30% by weight of calcium-containing substance based on the active ingredient, if necessary, based on the active ingredient It is characterized in that 20 to 30% by weight, the therapeutic agent of the present invention can solve or prevent the symptoms of hangovers in a short time without causing any side effects on the human body.

Description

Hangover treatment composition

The present invention relates to a therapeutic agent for treating a hangover resulting from alcohol overdose, and more particularly, to a hangover treatment agent mainly comprising potassium salt.

"Hangover" as a result of alcohol drinking is generally the main symptom of known symptoms is headache, hyperacidity, nausea, nausea, diarrhea and malaise. These symptoms have been treated in such a way as to alleviate one or both of the symptoms. Formulations proposed to alleviate all symptoms are described in US Pat. No. 3,829,569. However, this preparation should be administered in two separate fractions. This is because the ingredients are too large for a single dose to be required to achieve the desired therapeutic result. In addition, when the ingredients are mixed in a single dose, they interact in a way that adversely affects the stability of the formulation.

In addition, Korean Patent Application No. 94-23685 discloses a natural herbal composition for eliminating the root cause of the hangover. Its main components are root roots, green beans, red beans, hawthorn, glitches, seedlings, sign, celestial organs, peppermint, malt, and fructose.

However, all of the above techniques have some problems in terms of remission rate and effects of hangover symptoms.

On the other hand, looking at the conventional technique using potassium salt in the treatment of diseases, WO 94/22312 discloses a technique using a combination of potassium salt and thiazide diuretics for the treatment of osteoporosis, and potassium salt in WO 97/26897 A technique using a combination of magnesium and pyridoxine in preventing or treating migraine or stress headache is disclosed. However, this field is a field that has nothing to do with hangover elimination aimed at by the present invention.

The present invention is to solve the problems described above, it is an object of the present invention to provide a hangover treatment agent having a fast speed of relief of the hangover symptoms as well as no side effects even when administered as a single dose.

1 is a graph showing the change in blood alcohol concentration of rats following treatment administration,

2 is a graph showing the change in alcohol concentration in human blood following administration of a therapeutic agent.

The present invention is characterized by containing at least 50% by weight of potassium salt in the active ingredient, 20 to 30% by weight of calcium-containing substances and 20 to 30% by weight of the roots as necessary.

Hereinafter, the present invention will be described in detail.

Although the exact pharmacological mechanism of potassium salt, the main component of the present invention, has not been demonstrated, alcohol metabolism is increased by increasing the activity of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), which are alcohol metabolizing enzymes in the liver. It is believed to alleviate the symptoms of hangover by promoting the disease.

Calcium-containing materials also act similar to potassium salts, but there are many differences in their strengths, especially when they coexist with potassium salts.

Potassium salts usable in the present invention are K ₂ CO ₃ , KHCO ₃ , potassium acetate, potassium citrate, potassium gluconate, and the like, most preferred is potassium citrate. The calcium-containing material usable in the present invention is a natural calcium compound derived from a biological source and has a calcium content of 10% by weight or more, and examples include calcium citrate, calcium caseate, ash bone powder, keel, shell powder, shell powder and the like. .

The proper amount of potassium salt is 50% by weight or more based on the active ingredient, and the rest may include calcium-containing substances, foods having a healthy or refreshing effect, taste foods and other trace elements. One of the healthy foods is brown root. Puerariae Radix is Mesquite (Leguminosae) removing the jupi of kudzu (Pueraria thynbergiana Bentham) belonging to the root, and about 5~10mm be sliced finely uneven by the cube of ² cm or length 20~30, butterfly 5~6cm, about 1cm thick It is plate-shaped, and it is vertically cut, and its outer surface is grayish yellow to gray white bird. Brown root is a herbal medicine mainly used to relieve poisoning and to relieve browning and stomach irritation in Chinese medicine.

A suitable daily dose of potassium salt is 300-2500 mg, more preferably 1000-2000 mg, based on potassium citrate for normal weight adults. If it is less than this range, the hangover healing effect is insufficient, and if it exceeds this range, no further effect occurs.

For reference, the therapeutically or prophylactically effective amount of a pharmaceutically acceptable alkalized potassium salt is 40 to 400, more preferably 50 to 250 millimoles, based on 70 Kg of adult.

The therapeutic agent of the present invention tablets, coated tablets, capsules anhydrous powder of the composition as described above through conventional methods, tablets may contain conventional excipients, such as tablets, lactose, glocose, etc. Capsules can be used with conventional hard gelatin.

Embodiments of the present invention are as follows.

<Production Example 1>

Tablets were prepared by using starch as an excipient so that the content of potassium citrate per tablet was 10 mg.

<Production Example 2>

Prepared in the same manner as in Preparation Example 1, 2 mg of calcium caseate was added.

<Production Example 3>

Prepared in the same manner as in Preparation Example 1, but added 2 mg of root root.

<Example 1>

* Changes in blood alcohol levels of rats following treatment

40 male rats of 180-220 g body weight were fasted for 20 hours, and then 10 rats were used for each group divided into a control group and a first sample group to a third sample group. The first sample group was administered in Preparation Example 1, the second sample group in Preparation Example 2, and the third sample group was administered by mixing the tablets obtained in Preparation Example 3 with food, and the control group was given only food.

After 1 hour, 3 g of ethanol per 1 kg of body weight was orally administered to the control and sample groups, respectively. At 1 hour, 3 hours, 6 hours, and 9 hours after ethanol administration, blood was collected from the tail, and the collected blood was immediately reproteinated to measure the alcohol concentration and then averaged. The result is shown in FIG.

<Example 2>

* Changes in alcohol concentration in human blood following administration of therapeutic agent

The subjects were eight healthy adult males with no liver and renal dysfunction, no physical abnormalities, and within the range of ± 10% of their ideal weight. Before the start of the experiment, the subject was fully explained to the subject, and the subject was started after obtaining consent from the subject. Subjects with abnormal liver and renal function according to the following criteria were excluded from the subject.

<Exclusion Criteria>

1) In the case of liver dysfunction, that is, the former is twice the normal value and the latter is outside the normal range in the measurement of sGOT / sGPT and total protein / albumin.

2) Has experience of hypersensitivity to the drug, gastrointestinal tract, kidney, liver and kidney disease

3) If you have alcohol or other drug addiction

4) Other cases deemed inappropriate for this experiment

Eight subjects selected according to the above criteria were banned from ingesting food containing alcohol from three days before the experiment was started, and the experiment was performed after fasting for 8 hours or more on the day of the experiment. Thirty minutes prior to ethanol intake, 100 ml each of the same cup or placebo were taken by random double-blind method, and a crossover experiment was performed for each week with a 1-week washout period. Samples were prepared in the same manner as in Preparation Examples 1 to 3, but the content of potassium citrate was 500 mg, and the tablet containing calcium-containing substance and the gallbladder increased in this ratio were dissolved in sugar water, respectively, and placebo was sugar water. to be.

In the morning of the experiment, subjects were allowed to drink 1.3 g of ethanol per kg body weight over 30 minutes and fasted for 4 hours after the administration of ethanol to minimize the effects of food or drinking water on the ethanol dynamics during the experiment. The same menu was used during the crossover experiment. In addition, 4 hours after the administration of ethanol during the experimental period to limit the supply of water within 200ml per 3 hours, but the intake of other beverages was limited.

Somatic blood was collected in heparin (100U / ml) -filled vein in the forearm vein immediately before ethanol administration and 2ml at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours after the time of administration. Blood was taken from the heparinized vacuum tube and blood ethanol concentration was measured. The result is shown in FIG.

<Example 3>

* Experiment to improve hangover symptoms

Eight healthy adult men who met the criteria in Example 2 were administered three times at weekly intervals with the therapeutic (tablet) and the same amount of placebo used in Example 2 and ingested alcohol 30 minutes after administration. The subjective feeling and objective signs of the hangover after 12 hours (1.3 g / kg body weight) were evaluated according to the following evaluation criteria, and the average of the ratings was obtained. The results are shown in Table 1 below.

headache throw up Digestive disorder tired Window back Control 1.5 1.7 1.2 1.6 1.3 1st sample group 0.6 0.7 0.5 0.6 0.5 2nd sample group 0.5 0.7 0.4 0.5 0.5 3rd sample group 0.5 0.5 0.3 0.5 0.4

* Evaluation Criteria: Headache, Vomiting, Digestive Disorder, Tiredness, Pale (0: None, 1: Mild, 2: Severe)

As can be seen from the above embodiment, the therapeutic agent of the present invention can solve or prevent the symptoms of hangover in a short time without causing any side effects on the human body.

Claims (4)

Hangover treatment, characterized in that containing at least 50% by weight potassium salt. The hangover treatment according to claim 1, wherein the calcium-containing substance is added in an amount of 20 to 30% by weight based on the active ingredient. The hangover treatment according to claim 1, wherein the root is added to 20 to 30% by weight based on the active ingredient. The hangover treatment according to claim 1, wherein the potassium salt is potassium citrate.